Not medical advice. Talk to your provider before using any peptide. Full disclaimer
AOD-9604
Beginner tier: 200 mcg, daily · 12w on / 4w off · community consensus
Also known as: hGH fragment 177-191, hGH frag, Tyr-hGH177-191
A 12-week trial in 300 obese adults works out to about 2.6 kg of weight loss on 1 mg oral, versus 0.8 kg on placebo (Herd 2005 abstract, per FDA). Then the definitive Phase IIb trial of 536 subjects failed. The AOD-9604 peptide (also called hGH frag) is a 15-amino-acid fragment of human growth hormone (residues 177 to 191). It boosted lipolysis in obese rodents without raising blood sugar. Its molecular target is still unknown, per FDA's 2024 briefing. No human trial tested subcutaneous dosing; SC dosing comes from community practice, with zero published human SC pharmacokinetic data. The peptide community treats it as a mild stack add-on for body recomposition, typically paired with CJC-1295 and Ipamorelin at 300 to 500 mcg subcutaneous daily.
What Is AOD-9604?
About 2.6 kg of weight loss over 12 weeks on 1 mg a day by mouth, versus about 0.8 kg on placebo. That was the best arm of a 12-week trial of the AOD-9604 peptide (also called hGH fragment 177-191 or hGH frag, CAS 221231-10-3) in 300 obese adults. It was published only as a 2005 meeting abstract (Herd et al., Obesity Research). FDA's December 2024 PCAC briefing gives the rates: 0.22 kg a week versus 0.07 kg on placebo. Then the larger Phase IIb trial with 536 subjects ran for 24 weeks, added strict diet and exercise controls, and missed its primary endpoint. Metabolic Pharmaceuticals terminated the program in 2007.
How AOD-9604 works is still unsettled. Unlike full-length growth hormone, it does not bind the GH receptor [4]. Blood sugar stays flat. IGF-1 stays flat. Beta-3 adrenergic receptors seem to matter, but AOD-9604 has not been shown to activate them (details under How AOD-9604 Works). FDA's 2024 briefing says the molecular target is still unknown.
Community use looks different from the clinical program. Most users inject 300 to 500 mcg subcutaneously each morning on an empty stomach. Users usually justify that range by converting the 1 mg oral clinical dose with an assumed 40% oral bioavailability. FDA's 2024 briefing calls oral bioavailability unclear even in animals, and no human SC pharmacokinetic study exists. Across 50 to 150 Reddit threads in r/Peptides, the consensus is consistent: AOD-9604 is a mild add-on, not a primary fat loss tool. It performs best when stacked with CJC-1295 and Ipamorelin in a caloric deficit. Anyone expecting GLP-1-level results will be disappointed.
How AOD-9604 Works
AOD-9604 copies the fat-burning region of growth hormone without copying anything else. The peptide corresponds to amino acids 177 through 191 of hGH, plus a tyrosine at position 176 that stabilizes the fragment. In obese Zucker rats, Ng and colleagues found oral AOD-9604 cut weight gain by more than half and raised fat-tissue lipolysis [3].
The molecular target is still unknown, per FDA's December 2024 briefing. In obese mice, 14 days of AOD-9604 cut weight gain and raised fat oxidation [4]. Plasma glycerol, a marker of lipolysis, rose too, and blood sugar did not climb the way it did on full hGH. In cell tests, AOD-9604 did not bind the GH receptor or drive cell growth through it.
Beta-3 adrenergic receptors seem to be involved, but the evidence stops short of AOD-9604 activating them. Heffernan's group found it raised beta-3 receptor expression in obese mice. In beta-3 knockout mice, the 14-day course did not cut weight gain or raise lipolysis. In an acute test, though, it still raised energy expenditure and fat oxidation in those knockout mice. The authors concluded the lipolytic effect is not directly beta-3 mediated [2].
AOD-9604 also inhibits lipogenesis. Fat cells exposed to the fragment slow their conversion of circulating substrates into stored triglycerides. The dual action (accelerated breakdown plus reduced formation) produces a net shift in adipose tissue balance.
Fasted morning dosing is a community convention. Users reason that insulin from a meal blunts lipolysis, so they keep it low around the injection. None of the six human trials compared fed and fasted dosing, so the rule is untested for AOD-9604.
AOD-9604 Benefits
- AOD-9604 benefits center on targeted fat metabolism without the hormonal baggage of full-length growth hormone.
- A 12-week trial in 300 obese adults works out to about 2.6 kg of weight loss at 1 mg oral, versus about 0.8 kg on placebo. FDA's December 2024 PCAC briefing took those rates (0.22 vs 0.07 kg a week) from a 2005 meeting abstract. Waist circumference fell faster than placebo at every dose.
- No blood sugar disruption. AOD-9604 does not bind the GH receptor, so insulin sensitivity, fasting glucose, and HbA1c stay unaffected. Users managing metabolic concerns prefer this profile.
- Zero IGF-1 elevation. In the human trials, serum IGF-1 did not change versus placebo (Stier 2013 safety review of six trials). The growth and acromegalic features of exogenous GH don't apply; the 12-week oral trial's cancer reports are covered under Side Effects.
- Stacks well with GH secretagogues. The most common community protocol pairs AOD-9604 with CJC-1295 and Ipamorelin; direct lipolysis plus GH-axis pulsing is why this trinity stack dominates r/Peptides threads.
- No receptor desensitization reported. Clinical and community data both show consistent response across 12-week cycles. Users don't need to escalate doses over time.
- GRAS status for oral use (FDA designation as a food ingredient). This applies only to oral ingestion, not injectable forms, but it reflects a favorable oral safety profile across multiple human studies.
AOD-9604: Science vs Community Consensus
12-week oral trial (300 subjects, 1 to 30 mg/day; 2005 meeting abstract, per FDA): 1 mg arm lost 0.22 kg/week vs 0.07 kg/week on placebo (about 2.6 vs 0.8 kg).
Read the evidence (key study, limitations)
Phase IIb (536 enrolled, 24 weeks, 0.25 to 1 mg/day oral): primary endpoint FAILED when rigorous diet/exercise controls were applied. Pharmaceutical program terminated 2007. No published human SC pharmacokinetic or efficacy data. Four of six trials were oral; two gave single IV doses.
Herd et al. 2005, Obesity Research meeting abstract (12-week oral trial, 300 adults), as summarized in FDA's December 2024 PCAC briefing; Stier et al. 2013 (safety of six trials, about 900 adults); Ng et al. 2000 (PMID 11146367): obese Zucker rats
Phase IIb failed. No SC clinical data. GRAS designation is for oral use only. Injectable doses come from community practice, not a trial. The oral trial doses cannot be converted to SC doses: oral bioavailability is unclear even in animals (FDA PCAC briefing, December 2024). Half-life SC not established.
Mild body recomposition agent, not a primary fat-loss tool.
Read the reports (what users report 5, common issues 5)
Community sentiment is cautiously skeptical: valued as a clean, non-hormonal adjunct to GH secretagogue or GLP-1 stacks. Rarely used solo by experienced users. Consensus has shifted: AOD-9604 is positioned as a "stack add-on," not a standalone weight loss treatment.
- Mild abdominal fat reduction without muscle loss
- No blood glucose or insulin impact: preferred by insulin-sensitive users
- No IGF-1 elevation: valued by users avoiding full GH effects
- Clean tolerability profile: injection site reactions are the only common complaint
- Stackable with GLP-1s as a direct lipolysis add-on
- "Waste of money": highly variable individual results; many see minimal effect
- No appetite suppression (sharp contrast to GLP-1 agonists)
- Results plateau quickly without caloric deficit and exercise
- Expensive per-cycle cost given uncertain efficacy
- Compounding regulatory gray zone increasing sourcing difficulty
Community SC doses (300–500 mcg) come from user practice, not from a trial. No published figure converts the oral trial doses to SC: FDA's December 2024 briefing calls oral bioavailability unclear, even in animals. Community expectation of modest fat-loss aligns with Phase IIa data, but community ignores that the definitive Phase IIb trial failed. No SC clinical efficacy or safety data exist.
AOD-9604 Dosage Guide
Start at 200 to 250 mcg for the first two weeks. There's no rush to the full dose, and you'll want to confirm tolerability before committing to a 12-week run.
Reconstitution math for a 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg/mL, or 25 mcg per unit on a 100-unit insulin syringe. For a 250 mcg dose, draw 10 units. For 300 mcg, draw 12 units. For 500 mcg, draw 20 units.
Community protocols treat fasted dosing as non-negotiable. The logic is that insulin from a meal blunts fat breakdown; none of the six human trials compared fed and fasted dosing. No food, no cream in coffee, no BCAAs for at least two hours before injection. Wait 30 to 60 minutes after injection before eating.
The thing most beginners miss: AOD-9604 is not a GLP-1. There's no appetite suppression. You won't feel different. Track progress with waist circumference or DEXA, not the bathroom scale; scale weight poorly reflects what this peptide actually does.
A 5 mg vial at 400 mcg daily lasts 12.5 days. A full 12-week course burns through roughly 7 vials ($315 to $525 at current research-chemical pricing).
Cycling Protocol
No receptor desensitization reported, but cycling is still recommended. Can be run longer if well-tolerated.
No receptor desensitization has been documented with AOD-9604 in clinical trials or community use. Cycling is implemented as a precautionary practice to allow observation for cumulative effects (immunogenicity, injection site changes) and to assess on/off response. The pharmaceutical program was terminated before long-term continuous dosing studies were completed, so cycling is conservative rather than mechanistically driven.
- Injection site nodules or lipodystrophy developing at any site
- Loss of response after initial fat loss (plateau at week 8–10 signals diminishing returns)
- Any unexpected systemic symptoms that resolve during off-period (would suggest AOD-9604 as cause)
- Immunogenicity signal: increased local reaction severity over time
Or use the universal Peptide Calculator for any peptide.
AOD-9604 Protocols by Goal
Expected: Modest fat reduction (0.5–1.5 kg) primarily in abdominal area when combined with caloric deficit. Many users report no measurable effect without diet adherence.
Monitor: Body weight + waist circumference weekly. Scale weight alone is unreliable.
How to Use AOD-9604
- 1Step 1
Remove the 5 mg AOD-9604 vial and bacteriostatic water from refrigeration. Let both reach room temperature for 5 to 10 minutes.
- 2Draw 2 mL of bacteriostatic water using a mixing syringe
Inject slowly along the glass wall of the vial. Do not squirt directly onto the lyophilized powder. Swirl gently until dissolved; never shake.
- 3Label the vial with the reconstitution date
You now have 2,500 mcg/mL. Each unit on a 100-unit insulin syringe equals 25 mcg.
- 4For a 250 mcg dose, draw to the 10-unit mark
For 300 mcg, draw to 12 units. For 400 mcg, draw to 16 units. For 500 mcg, draw to 20 units.
- 5Clean the injection site with an alcohol swab
Pinch a fold of abdominal subcutaneous fat near the navel. Insert a 29 to 31 gauge, half-inch needle at a 45-degree angle.
- 6Inject slowly and steadily
Hold for 5 seconds before withdrawing.
- 7Step 7
Rotate injection sites across four abdominal quadrants to prevent lipodystrophy.
- 8Inject first thing in the morning on an empty stomach
Wait at least 30 minutes before eating.
- 9Step 9
Return the reconstituted vial to the refrigerator immediately. Use within 4 weeks.
Alternative Routes
The 12- and 24-week oral trials gave 0.25 to 30 mg a day (1 mg/day was the best arm); shorter oral studies went up to 54 mg. No oral-to-SC conversion exists: FDA calls oral bioavailability unclear even in animals, and no study has tested SC dosing.
GRAS status applies to this route. The only route given daily in human trials. However, compounded or research-grade oral capsules are rarely used by the community: the injectable format dominates despite having no clinical trial basis.
Rabbit study used intra-articular injection with HA; no dose translation to humans established
2024 PMC review (PMC11556548) cited this cartilage regeneration data. Not a community practice. Do not use intra-articular without clinical evidence.
AOD-9604 Stacking Protocols
Works With
Most cited community stack. CJC-1295 triggers GH pulse; AOD-9604 adds targeted lipolysis. Rationale: complementary mechanisms: GH-axis stimulation + direct fat-cell targeting.
CJC-1295 100–200 mcg + AOD-9604 300 mcg, fasted AM daily
Almost always included in the CJC-1295 + AOD-9604 trinity stack. Ipamorelin provides the GHRP pulse to complement CJC-1295 GHRH effect. Selective GH release without cortisol/prolactin spikes.
Ipamorelin 100–200 mcg + CJC-1295 100–200 mcg + AOD-9604 300–500 mcg, fasted AM
Body recomposition + healing stack. BPC-157 targets musculoskeletal repair while AOD-9604 drives fat loss. Popular in users doing resistance training or recovering from injury while cutting.
BPC-157 250–500 mcg + AOD-9604 300–500 mcg, fasted AM or pre-workout
Emerging stack: AOD-9604 as a lean-mass-preserving direct lipolysis add-on during GLP-1 cycle. No clinical data. Rationale is mechanistic complementarity (GLP-1: appetite suppression; AOD-9604: direct adipocyte lipolysis).
How much does AOD-9604 cost?
Typical price
$8.00 to $11.39 per mg
Middle half of 85 US prices for 5 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
AOD-9604 Side Effects
The Phase IIb trial of 536 subjects over 24 weeks produced the largest safety dataset. Headache was the most frequently reported adverse event in the oral formulation groups.
Four of the six human trials used oral capsules or tablets, and two gave single IV infusions (Stier 2013). Zero published human safety data exist for subcutaneous injection. Every subcutaneous safety claim is extrapolated from oral and single-dose IV data. That distinction matters because local tissue reactions, immunogenicity potential, and injection site effects cannot be inferred from swallowed capsules. FDA PCAC specifically cited manufacturing impurity risks and immunogenicity concerns for compounded injectable forms in their December 2024 review.
Published adverse events from the human trials (Stier 2013, a sponsor-funded safety review of about 900 adults):
Headache: most common. Adverse events overall ran at rates similar to placebo, mostly mild or moderate.
Digestive events (diarrhea, flatulence, nausea) came next. Headache, diarrhea and flatulence were more frequent at 54 mg a day in a 7-day trial.
Five people had serious adverse events in the 12-week oral trial, which gave 1 to 30 mg a day or placebo to 300 adults. Per FDA's December 2024 briefing, the 20 mg arm had basal cell carcinoma, a lipoma and squamous cell carcinoma. Breast cancer came at 5 mg and malignant melanoma at 10 mg. The investigator judged none related to AOD-9604, noting no cancers at the top 30 mg dose. FDA flagged the cancers as a concern; the reports held too little detail to judge whether AOD-9604 played a part.
Two smaller trials, per the same FDA briefing, logged events judged possibly related to AOD-9604. In an oral dose-escalation study, the 54 mg dose drew two serious adverse events: diarrhea, judged possibly related, and pneumonia, judged unrelated. In an IV study, one case of severe chest tightness at 50 mcg/kg was judged possibly related. So were five reports of mild or moderate euphoria, with none on placebo.
No clinically meaningful changes in blood glucose, insulin or IGF-1 were seen versus placebo.
Community-reported side effects from subcutaneous use (r/Peptides, approximately 50 to 150 threads):
Injection site reactions are the primary complaint. Redness, mild swelling, and induration at the injection site affect most new users. These are cosmetic and self-resolving. Diluting to a lower concentration, warming the vial to room temperature, and slowing injection speed all help.
Lipodystrophy at injection sites has been reported with poor site rotation. Rotate across four abdominal quadrants minimum.
Quality risk is a real factor. AOD-9604 is a 15-residue peptide requiring precise disulfide bridge formation during synthesis. Purity varies widely across unregulated research-chemical products. Low-purity preparations carry higher immunogenicity and local reaction risk. Only lot-specific HPLC and LC-MS data showing 98% or higher purity can confirm a batch.
AOD-9604 is WADA-prohibited (category S2, Growth Hormone Fragments) and detectable via mass spectrometry [5]. The Essendon Football Club scandal in 2012 involved roughly 34 AFL players who received AOD-9604 injections; several faced bans.
AOD-9604 has not been studied in pregnancy or breastfeeding. No pediatric data exist. Active malignancy is a contraindication because effects on tumor growth have not been evaluated. Known hypersensitivity to the peptide or excipients is an absolute contraindication.
When to stop: discontinue if injection site nodules develop, if local reaction severity increases over successive weeks (potential immunogenicity signal), or if unexpected systemic symptoms appear that resolve during off-cycle periods. Any hypoglycemia symptoms when stacking with GLP-1 agonists or secretagogues warrant immediate discontinuation and medical evaluation.
Common Issues & Solutions
No results at 300 mcg: Verify fasted state is strict (no food, coffee with cream, BCAAs for ≥2h prior). Community protocols assume insulin blunts the effect, though none of the six human trials tested fed versus fasted dosing.
No results despite fasting: no study has tested SC dosing, so no SC dose has a proven effect. Community protocols use 300 to 500 mcg and call it a non-response after 8 weeks at 400 mcg.
Injection site redness/swelling: Dilute to lower concentration (add more BAC water), warm vial to room temperature before injection, and slow the injection rate. Reactions are typically cosmetic and self-resolving.
Minimal fat loss vs GLP-1 expectations: AOD-9604 is not a GLP-1 agonist. The Phase IIb trial failed. Realistic outcomes are 0.5–2 kg over 12 weeks in caloric deficit: not the 15–22% body weight reductions seen with semaglutide/tirzepatide.
Uncertain about real vs. placebo effect: Track with DEXA or circumference measurements, not scale weight alone. AOD-9604 does not cause fluid retention or muscle gain, so scale changes directly reflect composition shifts.
Ask AI about this page
Ask AI for a second opinion on AOD-9604 dosing and side effects
Contraindications
- Pregnancy or breastfeeding: no safety data in these populations
- Active malignancy or history of cancer: effects on tumor growth not studied
- Known hypersensitivity to AOD-9604 or any excipients
- Children and adolescents under 18: not studied in pediatric populations
Drug Interactions
- Insulin and oral hypoglycemics: although AOD-9604 does not directly affect blood sugar, monitor glucose when combining with diabetes medications
- Thyroid medications: fat metabolism changes may alter thyroid hormone requirements; monitor levels
- Other lipolytic agents (e.g., growth hormone, clenbuterol): potential additive effects on fat mobilization; use with caution
- Anticoagulants: no known interaction, but as with all injectable peptides, monitor for injection site bruising
Product Quality
AOD-9604 is a 15-residue peptide (plus Tyr176) that requires precise disulfide bridge formation. Research-chemical products are unregulated; purity varies widely. FDA PCAC (December 2024) specifically cited manufacturing impurity risks and immunogenicity concerns for compounded/injectable forms. No FDA-approved or pharmacopoeial standard exists for injectable AOD-9604.
- Only lot-specific HPLC + MS purity data (>98%) confirms what a given vial holds
- A useful Certificate of Analysis (CoA) verifies sequence mass by LC-MS: generic purity % is insufficient
- Avoid pre-blended AOD-9604 vials (CJC-1295/Ipamorelin blends) where you cannot independently verify individual component purity
- Be aware that compounded injectable AOD-9604 is in a regulatory gray zone post-December 2024 PCAC recommendation; formal compounding ban may follow FDA rulemaking
- Store lyophilized at 2–8°C (not room temperature) for reliability: despite label claims, room temperature storage accelerates degradation in warm/humid climates
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Body weight + waist circumference | Weekly throughout cycle | Individual baseline: trend toward decrease in waist circumference over 12 weeks |
| DEXA scan (optional) | Baseline and week 12 | Not listed |
| Fasting glucose | Baseline; week 6 if stacking with secretagogues or GLP-1s | Not listed |
| Injection site assessment | Each injection | Not listed |
Primary outcome measure. Scale weight is misleading if combining with a secretagogue stack (water retention). Waist circumference reflects visceral fat reduction more accurately.
Definitive body composition assessment to distinguish fat mass loss from weight change. AOD-9604 should not affect lean mass or bone density.
AOD-9604 alone does not affect glucose. Monitoring is relevant only when stacked with GH secretagogues (which can cause transient hyperglycemia) or GLP-1s (hypoglycemia risk in deficit).
Lipodystrophy or nodule formation indicates inadequate site rotation or too-high local concentration. Rotate sites across abdominal quadrants.
AOD-9604 Before and After
Body adjusts to the peptide. No visible fat loss yet. Mild injection site redness may occur. Establish consistent fasted morning dosing routine.
Early metabolic shifts begin. Some users notice reduced abdominal bloating. In obese mice, fat oxidation rose after 14 days (PMID 11673763); the human timing is unknown, and scale weight may not change.
Measurable fat loss becomes apparent, particularly in the midsection. Clothes may fit differently. The oral trial's average rate (0.22 kg a week at 1 mg) works out to roughly 1 to 2 kg of weight by week 8.
Continued steady fat loss. Clinical trial subjects on 1 mg/day lost an average of 2.6 kg over 12 weeks. Body composition improvements are visible. No receptor desensitization observed.
Ongoing fat metabolism support. Results plateau as body reaches a new set point. Can extend beyond 12 weeks if well-tolerated. Pair with exercise and caloric control for best outcomes.
What to Expect
Weeks 1 to 2 (Adaptation): Nothing visible happens yet. Most users notice zero change. A small number report mild energy shifts. Mild injection site redness is the most common complaint in this window. Use this time to lock in your fasted morning routine.
Weeks 3 to 4 (Early metabolic shift): In obese mice, fat oxidation rose after 14 days of dosing; the human timing is unknown. Some users report subtle reduction in abdominal bloating and slightly improved definition if already lean. Injection site reactions typically settle. Headache was the top adverse event in oral trials and may appear here.
Weeks 5 to 8 (Measurable fat loss): The 12-week oral trial reported only average weekly rates, 0.22 kg a week at 1 mg versus 0.07 kg on placebo. No study has tested subcutaneous dosing, so SC use has no trial rate to compare. Fat loss becomes visible around the abdomen. Clothes fit differently. Community-reported change averages 0.5 to 1.5 kg of measurable fat in this window, though individual variation is high. Side effects are typically gone by this point.
Weeks 9 to 12 (Plateau approach): The 12-week trial works out to about 2.6 kg of total weight loss at 1 mg. The Phase IIb trial at 24 weeks showed no benefit over placebo when exercise controls were applied. A plateau is expected. Most users who respond have responded by week 10. Continuing past 12 weeks without changing the protocol yields diminishing returns.
Detailed Timeline: Science vs Community
No human data on timing. In obese mice, 14 days of dosing raised fat oxidation and plasma glycerol, a lipolysis marker. No measurable fat change in this period.
Most users notice nothing. A small subset report mild energy increase. Establish fasted routine.
When fat oxidation rises in humans is unmeasured. In the 4-week IV and oral trials, weight loss did not differ significantly from placebo (FDA PCAC briefing, December 2024).
Subtle reduction in abdominal bloating. Some notice improved definition if already lean. No dramatic fat loss yet.
The 12-week oral trial reported only average weekly rates: 0.22 kg a week at 1 mg versus 0.07 kg on placebo (FDA PCAC briefing, December 2024). No study has tested SC dosing.
Fat loss visible around abdomen. Clothes fit differently. Average community-reported change: 0.5–1.5 kg measurable fat in this window, highly variable.
The 12-week oral trial reported 0.22 kg a week at 1 mg versus 0.07 kg on placebo, about 2.6 kg in total (FDA PCAC briefing, 2024). Phase IIb at 24 weeks showed no benefit over placebo with exercise controls. Plateau is expected.
Results slow. Most users who are going to respond have responded by week 10. Continuing past 12 weeks yields diminishing returns without a protocol change.
Pharmacokinetics
Source: IV t1/2 about 3 min in pigs and 4 min in rat blood in vitro (Moré and Kenley 2014, per FDA PCAC briefing, December 2024); no established SC half-life
Molecular Profile
Is AOD-9604 Legal?
AOD-9604 is not FDA-approved for any therapeutic indication. The pharmaceutical development program (Metabolic Pharmaceuticals, Australia) was terminated in 2007 after Phase IIb failure. The compound holds GRAS status strictly as an oral food additive. That designation does not apply to injectable use.
FDA PCAC voted in December 2024 to recommend that AOD-9604 not be included on the 503A Bulks List for pharmacy compounding. Formal rulemaking is pending. If finalized, compounded injectable AOD-9604 from 503A pharmacies would become unavailable. Research-chemical sellers still offer it. Selling it for people to inject is not legal without FDA approval, and a "research" label does not change that (21 CFR 201.128).
AOD-9604 is WADA-prohibited under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). It is detectable via mass spectrometry (Drug Testing and Analysis 2015)[5]. Competitive athletes must not use it.
This content is for informational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Evidence grade: Phase 2 trial (Peptide Evidence Gap, October 2026)
Who Should Consider AOD-9604
- Adults with BMI ≥30 seeking non-hormonal fat loss support
- Individuals who want fat reduction without IGF-1 or blood sugar effects
- Adults looking for a GRAS-status peptide option for body recomposition
- Patients who cannot tolerate GLP-1 receptor agonists
- Adults with stubborn adipose deposits resistant to diet and exercise
Related Peptides
What Changed for AOD-9604
- Evidence
Corrected Oct 17, 2026: AOD-9604's human side effects now cite the six sponsor trials, not mouse and rat studies, per FDA's December 2024 PCAC briefing.
Before: Credited oral-trial adverse events to PMID 10950816 and 11146367 (a mouse study and a rat study) and said all six trials were oral After: Cites the six human trials summarized by Stier 2013 (about 900 adults; four oral, two single IV): headache most common, adverse events similar to placebo
What this does not mean: No new study was published. Two of the six trials gave single IV doses, so the page no longer says every trial was oral. No human study has tested subcutaneous injection.
Source: FDA, Pharmacy Compounding Advisory Committee briefing document for AOD-9604-related bulk drug substances, December 4, 2024 (memo dated November 5, 2024): the six sponsor trials summarized by Stier et al. 2013, two IV and four oral (pp. 32-35) (opens in a new tab) · Saved copy
- Safety
Added Oct 17, 2026: AOD-9604's 12-week oral trial had serious adverse events, cancers among them, judged unrelated by its investigator, per FDA's 2024 briefing.
Before: Listed headache and digestive events from the human trials and no serious adverse events After: Adds the 12-week trial's five serious adverse events (basal cell and squamous cell carcinoma, a lipoma, breast cancer, malignant melanoma), judged unrelated by the investigator, FDA could not assess relatedness; plus events judged possibly related in two smaller trials (diarrhea at 54 mg oral, severe chest tightness at 50 mcg/kg IV, euphoria)
What this does not mean: No new study was published; the serious-event data come from Stier 2013's summary of the sponsor trials, via FDA in 2024. FDA found too little detail to judge whether the cancers were related. No human study tested subcutaneous use.
Source: FDA, Pharmacy Compounding Advisory Committee briefing document for AOD-9604-related bulk drug substances, December 4, 2024 (memo dated November 5, 2024): adverse events in the six sponsor trials summarized by Stier et al. 2013 (pp. 34-35) and FDA's caveat on them (p. 36) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism (Heffernan et al., Am J Physiol Endocrinol Metab 2000; tested AOD-9401, the precursor fragment, in obese mice and human fat tissue) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Effects of hGH and its lipolytic fragment (AOD9604) on lipid metabolism in obese mice and beta-3-AR knock-out mice (Endocrinology 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (Horm Res 2000) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with hGH or a modified C-terminal fragment (Int J Obes 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Detection and in vitro metabolism of AOD9604 (Drug Test Anal 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (Stier et al., J Endocrinol Metab 2013) (opens in a new tab)Review
- FDA: Evaluation of AOD-9604-related bulk drug substances, Pharmacy Compounding Advisory Committee briefing (December 4, 2024) (opens in a new tab)Review
- Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health (J Endocrinol Metab) (opens in a new tab)Review
- Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis (Liao et al., Cartilage 2024) (opens in a new tab)PubMed 39291443PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is AOD-9604?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 50–150. Community mentions on Reddit: ~50–150 threads (r/Peptides, mostly in stacking threads). Open r/Peptides (opens in a new tab).
20 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.